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Background
In developed countries, the morbidity and mortality in Human 
Immunodeficiency Virus (HIV) patients is significantly induced by 
chronic Hepatitis C Virus (HCV) co-infection. It is estimated to have 
about one-third of HIV patients co-infected with HCV. These patients 
usually require immediate HCV treatment as they tolerate poorly 
towards antiretroviral treatment, progress more rapidly to end-stage 
liver disease and often lead to death [1,2]. 
For decades, the standard therapy for HCV infection relies on the 
combination of pegylated interferon and ribavirin (PEG-IFN/RBV). 
This treatment is known to be less effective towards HIV/HCV co-
infected patients, with a lower rate of Sustained Virological Response 
(SVR) and a higher rate of viral relapse upon treatment completion 
[3,4]. Recent studies identified two Single Nucleotide Polymorphisms 
(SNPs) rs12979860 and rs8099917 that located near interleukin-28B 
(IL-28B) and acted as important baseline predictors for PEG-IFN/RBV 
treatment responses. Strong association between favourable genotypes 
(C/C for rs12979860 and T/T for rs8099917) and high rate of SVR were 
observed in several genome wide association studies [5-8]. 
Clinical management on HIV/HCV co-infected patients is always 
more complicated than mono-infected patients. Several commercial 
assays and sequencing are the major IL-28B polymorphisms detection 
methods, yet they are relatively expensive and time-consuming. This 
study aimed to develop a rapid and cost-effective duplex HybProbe 
real-time assay to detect both rs12979860 and rs8099917 SNPs in a 
single reaction and estimate the prevalence of IL-28B, HIV-1 and HCV 
subtypes among co-infected patients in this locality. 
Objectives
To evaluate the performance of a newly developed HybProbe 
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Abstract
 Conventional treatment for chronic HCV infection relies on the combination of peg-interferon and ribavirin 
therapy. Both interleukin-28B (IL-28B) polymorphisms and HCV genotypes serve as the strongest predictive values 
for therapeutic prognosis. The treatment regimens for HIV/HCV co-infected patients are more complex and dependent 
on various host immune and viral factors. A rapid and cost-effective IL-28B genotyping tool is therefore crucial to 
assist clinicians on better patient management. This study aimed to evaluate the performance of a newly developed 
HybProbe duplex real-time PCR assay in detecting IL-28B polymorphisms on rs12979860 and rs8099917, and 
to estimate the prevalence of IL-28B polymorphisms among HIV/HCV co-infected patients in Hong Kong. A total 
of 88 HIV/HCV co-infected patients were recruited at the Integrated Treatment Centre during 2009 to 2014. IL-
28B polymorphisms on rs12979860 and rs8099917 were determined by an in-house HybProbe assay with melting 
curve analysis. For assay evaluation, IL-28B polymorphisms of 46 samples with diverse HIV/HCV genotypes were 
confirmed by Sanger sequencing. Both in-house HybProbe assay and sequencing results for IL28B polymorphisms 
determination were completely concordant. Among the 88 HIV/HCV co-infected, the frequency of rs12979860 wild-
type (C/C) was 88.6%, heterozygous mutant (C/T) was 9.1% and remaining 2.3% homozygous mutant (T/T). The 
prevalence of IL-28B polymorphisms in rs8099917 was slightly differed, which had 90.9% wild-type (T/T), 6.8% 
heterozygous mutant (G/T) and 2.3% homozygous mutant (G/G). This novel duplex assay could allow clinicians to 
make early decision on treatment option for HIV/HCV co-infected patients by detecting rs12979860 and rs8099917 
polymorphisms simultaneously.
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duplex real-time PCR assay in detecting IL-28B polymorphisms on 
rs12979860 and rs8099917, and to estimate the prevalence of IL-28B 
polymorphisms among HIV/HCV co-infected patients in Hong Kong. 
Study Design
A total of 88 HIV/HCV co-infected patients were recruited at the 
Hong Kong Government Integrated Treatment Centre during 2009 to 
2014. Whole blood samples were collected after patient consent. The 
IL-28B polymorphisms on rs12979860 and rs8099917 of all samples 
were detected by the HybProbe assay with melting curve analysis. 
The duplex PCR assay was amplified by LightCycler® FastStart DNA 
Master HybProbe (Roche Diagnostics, Germany), with two pairs of 
primers and hybridization probes specifically targeting rs12979860 and 
rs8099917 (Table 1). For assay evaluation, IL-28B polymorphisms of 
46 samples were further confirmed by Sanger sequencing. HCV viral 
load was quantitated by Abbott m2000 RealTime HCV assay (Abbott 
Laboratories, USA) while HIV-1 and HCV genotypes were confirmed 
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by our in-house methods [9,10]. Statistical analysis was performed by 
Graphpad Prism version 6(Graphpad software, California, US).
Results
Basic demographic characteristics of HIV/HCV co-infected 
patients in this study are presented in Table 2. There were 82 males 
(93.2%) included in this study, with an overall median age at 39 (range 
21 – 63 years). Nearly 65% of the study population were Chinese 
with approximately 33% non-Chinese Asians. The in-house HIV-1 
genotyping analysis revealed that the patients were infected by subtype 
B (20.5%), CRF01_AE (47.7%) and C or BC recombinants (15.9%). 
HCV genotypes were detected in 71 patients, including genotype 
1/1a/1b (30.7%), 3a/3b (26.1%) and 6a/6d/6e (23.9%). Due to low HIV-1 
or HCV viral load at sample collection, about 15 – 20% of the co-infected 
patients were unable to have either or both viral genotyping results. 
The HybProbe assay performance was evaluated among 46 co-
infected samples, using Sanger sequencing as gold standard. Diverse 
HIV-1 subtypes (5 subtype B, 3 subtype C, 29 CRF01_AE, 4 CRF07_BC, 
1 CRF08_BC and 4 undetermined) and HCV genotypes (2 genotype 1, 9 
genotype 1a, 6 genotype 1b, 2 genotype 3a, 1 genotype 3b, 9 genotype 6a, 1 
genotype 6d, 3 genotype 6e and 13 undetermined) samples were included 
for evaluation. Sanger sequencing required two individual reactions 
and manual sequence proof-reading whereas in-house HybProbe assay 
required melting curve analysis to interpret the SNPs on rs12979860 and 
rs8099917. Rs12979860 C/C wild-type had a melting peak at 64℃ ± 1℃ 
while T/T mutant had a lower melting temperature at 54℃ ± 1℃ (Figure 
1A). For rs8099917, T/T wild-type melted at 64℃ ± 1℃ whereas mutant 
G/G melted at 57℃ ± 1℃ (Figure 1B). Heterozygous mutants (C/T of 
rs12979860 and T/G of rs8099917) could be typically interpreted when 
both melting peaks of wild-type and mutant were seen. Both systems 
rs12979860
Forward Primer 5’- GCGCTTATCGCATACGGCTA - 3’
Reverse Primer 5’- TCACAGAAGGGAGCCCTGCC - 3’
Sensor Probe 5’- CGAAGGCGCGAACCAGG-Fluorescein - 3’
Anchor Probe 5’- LC Red 640 - TGAATTGCTCCGCGCTCCC-Phosphate - 3’
rs8099917
Forward Primer 5’- AAGTAACACTTGTTCCTTGTAAAAGATTCC - 3’
Reverse Primer 5’- CGCTATAATTAAAGATGTGGGAGAATGCAA - 3’
Sensor Probe 5’ - CCTTTCTGTGAGCAATTTCACCCAA- Fluorescein - 3’
Anchor Probe 5’ - LC Red 705 - TGGAACCATGCTGTATACAGTTTGGTAGC-Phosphate – 3’
C or T indicates SNPs position.
Table 1:  Primers and probes for IL-28B Genotyping assays.
Total rs12979860 P-value* rs8099917 P-value*
n (%) CC CT/TT TT TG/GG
(n=78) (n=10) (n=80) (n=8)
Gender 0.5260 0.4455
Male 82 (93.2) 73 (83.0) 9 (10.2) 75 (85.2) 7 (8.0)
Female 6 (6.8) 5 (5.7) 1 (1.1) 5 (5.7) 1 (1.1)
Ethnicity 0.7117 0.2572
Chinese 57 (64.8) 50 (56.8) 7 (8.0) 50 (56.8) 7 (8.0)
Asian 29 (33.0) 27 (30.7) 2 (2.3) 28 (31.8) 1 (1.1)
Undetermined 2 (2.3) 1 (1.1) 1 (1.1) 1 (1.1) 1 (1.1)
Risk of Infection N/A N/A
IDU 18 (20.5) 17 (19.3) 1 (1.1) 17 (19.3) 1 (1.1)
Homosexual 7 (8.0) 7 (8.0) -- 7 (8.0) --
Heterosexual 2 (2.3) 2 (2.3) -- 2 (2.3) --
Undetermined 61 (69.3) 52 (59.0) 9 (10.2) 54 (61.4) 7 (8.0)
HIV-1 subtypes 0.0662 0.1006
B 18 (20.5) 13 (14.8) 5 (5.7) 14 (15.9) 4 (4.5)
CRF01_AE 42 (47.7) 39 (44.3) 3 (3.4) 40 (45.5) 2 (2.3)
C or CRF07_BC or
CRF08_BC 14 (15.9) 13 (14.8) 1 (1.1) 13 (14.8) 1 (1.1)
PCR -ve 14 (15.9) 13 (14.8) 1 (1.1) 13 (14.8) 1 (1.1)
HCV genotypes 0.1267 N/A
1 / 1a / 1b 27 (30.7) 26 (29.5) 1 (1.1) 27 (30.7) --
3a / 3b 23 (26.1) 18 (20.5) 5 (5.7) 18 (20.5) 3 (3.4)
6a / 6d / 6e 21 (23.9) 19 (21.6) 2 (2.3) 20 (22.7) 1 (1.1)
PCR -ve 17 (19.3) 15 (17.0) 2 (2.3) 15 (17.0) 2 (1.1)
N/A: Not available; -ve: negative; IDU: Intravenous drug users
*Statistics: Fisher’s exact tests
Table 2:  Basic demographic characteristics of HIV/HCV co-infected patients.
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Figure 1:  Melting curves and melting peaks analysis of rs12979860 (Figure 1A) and rs8099917 (Figure 1B) single nucleotide polymorphisms detection by in-house 
HybProbe assay. Heterozygous mutants could be interpreted when both melting peaks or wild-type and mutant were seen.
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concordantly detected two C/T and one T/T mutants of rs12979860, as 
well as one G/T and one G/G mutants of rs8099917. 
Among the 88 HIV/HCV co-infected patients in this locality, 
the frequency of rs12979860 wild-type (C/C) was 88.6%, while the 
frequency of C/T and T/T mutants was 9.1% and 2.3% respectively. The 
prevalence of IL-28B polymorphisms is rs8099917 was significantly 
differed (P < 0.0001, Fisher's exact tests), which had 90.9% wild-
type (T/T), 6.8% G/T and 2.3% G/G mutants. This study revealed no 
association between HIV-1 subtypes, HCV genotypes, ethnicities or 
gender between rs12979860 or rs8099917 unfavourable genotypes. 
Most of the patients had concordant wild-type or mutant genotypes 
between both rs12979860 and rs8099917. Exceptions were seen in 
one Asian and one patient with undetermined ethnicity as they had 
unfavourable C/T on rs12979860 but favourable wild-type T/T on 
rs8099917. 
Discussion
The identification of both rs12979860 and rs8099917 
favourable genotypes largely enhanced the rate of SVR in HIV/
HCV co-infected patients. To our knowledge, this is the first in-
house duplex IL-28B real-time HybProbe assay that successfully 
identifies both rs12979860 and rs8099917 SNPs simultaneously in 
one single tube. The HybProbe assay used LC-RED640 and LC-
RED705 acceptor dyes to detect both SNPs in a single run instead 
of individual sequencing reactions. The melting temperatures for 
both SNPs interpretation were also very distinct, which was 10℃ for 
rs12979860 and 6℃ for rs8099917, respectively. Traditional Sanger 
sequencing consists of several tedious experimental steps, including 
end-point PCR and capillary analysis, whereas the in-house duplex 
assay largely shortened the turnaround time from two days to two 
hours with at least 50% of running cost reduction. 
The in-house HybProbe assay achieved 100% concordant 
SNPs interpretation with the sequencing results. Both Chinese and 
Asians were included in this study, together with diverse HIV-1 and 
HCV genotypes, suggesting that the current assay would be largely 
applicable to global laboratories. Both HIV-1 subtype B and CRF01_
AE accounted for about 80% of local infections in Hong Kong [11]. A 
higher prevalence of CRF01_AE (47.7%) was noticed in our patients, 
whereas the prevalence for subtype B was relatively low (20.5%). 
Limited information on routes of infection was available at the time 
of study, though about a-fifth of the study population were infected 
via intravenous drug use. Conversely the prevalence of HCV genotype 
1, 3 and 6 were roughly similar, which was inconsistent with previous 
local studies, suggesting that the HIV/HCV co-infection might pre-
dominantly affect intravenous drug users with distinct epidemiological 
and transmission pattern. [10,12].
Clinical management among HIV/HCV co-infected patients 
usually induced more complications due to drug-drug interaction and 
patients’ immune status. Poor SVR rate was mainly associated with 
HCV genotype 1 and unfavourable IL-28B SNPs yet the information 
on other HCV genotypes and HIV co-infection was scarce. Two of 
our patients had C/T mutant on rs12979860 but wild-type T/T on 
rs8099917. Their treatment response towards 48-week of PEG-IFN/
RBV should be analysed in greater details to assess the impact of 
discordant IL-28B polymorphisms. Due to data availability, the HIV/
HCV treatment history and rate of SVR were insufficient for further 
investigation on the relationship between IL28B polymorphisms, 
HIV/HCV genotypes and treatment responses among HIV/HCV co-
infected patients. 
Conclusion
This study developed a simple and efficient IL28B duplex real-
time HybProbe assay with excellent performance on rs12979860 
and rs8099917 SNPs detection. The rapid detection allows clinicians 
to make early decision on treatment option and duration. Both C/C 
and T/T wild-types of rs12979860 and rs8099917 were prevalent in 
our locality. No significant association were observed between IL28B 
polymorphisms and HIV/HCV genotypes. 
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